03:51 AM EST - Oncolytics Biotech Inc : Provided a clinical and regulatory update on REO 033, the Company’s randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan and bevacizumab for the second-line treatment of patients with Rat Sarcoma-mutant, microsatellite stable metastatic colorectal cancer. Oncolytics Biotech Inc
shares N.ONCY are trading up $0.04 at $0.92.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7774334928205890
